Clinical Effects of Metformin on Fertility-sparing Treatment for Early Endometrial Cancer
The purpose of the study is to investigate the effects of metformin in addition to the conventional progestin therapy in the fertility-sparing treatment of early stage endometrial cancer.
Endometrial Cancer Stage I
DRUG: Metformin
Treatment response rates, Measurements of the primary lesion by the RECIST criteria, 3 months after the initiation of the treatment|Treatment response rates, Measurements of the primary lesion by the RECIST criteria, 6 months after the initiation of the treatment|Treatment response rates, Measurements of the primary lesion by the RECIST criteria, 9 months after the initiation of the treatment|Treatment response rates, Measurements of the primary lesion by the RECIST criteria, 12 months after the initiation of the treatment
The purpose of the study is to investigate the effects of metformin in addition to the conventional progestin therapy in the fertility-sparing treatment of early stage endometrial cancer.